drugset / Trial / NCT07373457
A Phase I Study of HW201877 in Healthy Subjects
Phase 1
Recruiting
104 enrolled
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase I, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and food effect (FE) of HW201877 in healthy subjects following (1) a single ascending dose (Part 1), which includes a single-dose, two-period crossover FE cohort; (2) a multiple ascending dose (Part 2).
Timeline
- Start
- 2025-06-26
- Primary completion
- 2026-03
- Completion
- 2026-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HW201877 | Unknown | — | Oral |